Cholesterol has long been embedded in public consciousness as one of the most important indicators of health, yet its simplicity hides a far more complex biological reality. Among its lesser-known components is lipoprotein(a), or Lp(a), a genetically determined blood marker that significantly increases the risk of heart attack, stroke, and aortic valve disease. According to reporting originally published by El País and analysed here by Finanacil Times, leading medical societies in both the United States and Europe now agree that every adult should measure Lp(a) at least once in their lifetime. Despite this consensus, its use in Spain’s public healthcare system remains inconsistent and fragmented.
Unlike standard cholesterol levels, Lp(a) is largely unaffected by diet or lifestyle and is instead almost entirely inherited. Studies suggest that around 20% of Europeans have elevated levels, often without any other abnormal cholesterol readings. This makes it particularly dangerous: patients may appear healthy under conventional screening while carrying a substantially higher risk of cardiovascular disease. Its hidden nature has made it a growing focus of preventive cardiology, even as clinical adoption remains uneven.
In Spain, access to Lp(a) testing depends heavily on geography, hospital protocols, laboratory capacity, and even individual physicians’ familiarity with the marker. In some regions, the test is readily available; in others, it is rarely requested or not incorporated into routine screening at all. This patchwork system means that whether a patient is tested can depend less on medical necessity than on administrative structure or local clinical culture.
Daniel Escribano, a lipid disorder specialist with the Spanish Society of Family and Community Medicine (semFYC), has described the situation as highly heterogeneous. According to him, access often depends on institutional decisions, hospital agreements, and the interest of specific departments such as cardiology or endocrinology. In practice, this creates a system where access to a globally recommended test can vary significantly depending on the patient’s location within the country.
Despite growing international consensus, some Spanish clinicians caution against universal screening without nuance. Escribano argues that while evidence supports at least one lifetime measurement, cost-effectiveness must be considered. Lp(a) testing is more expensive than standard cholesterol panels and, crucially, there is currently no specific treatment that directly lowers it in routine clinical practice. This raises questions about how widely it should be deployed, particularly in low-risk individuals where the result may not change immediate management.
He illustrates this with a clinical example: in a young, otherwise healthy patient with moderately elevated LDL cholesterol, knowing Lp(a) levels may not significantly alter treatment decisions. However, in patients with intermediate or unclear cardiovascular risk, the test can provide valuable additional information that may justify more aggressive prevention strategies, including tighter control of blood pressure, cholesterol, and lifestyle factors.
Rodrigo Alonso, a physician specialising in metabolic health and cardiovascular risk, supports this more targeted interpretation. He notes that while no direct treatment exists for Lp(a), controlling other risk factors can dramatically reduce overall cardiovascular risk even in patients with elevated levels. In his view, the clinical value of the test lies not in direct intervention on Lp(a) itself, but in refining risk assessment and guiding more intensive preventive care.
This perspective aligns with the growing view that Lp(a) should be measured at least once in adulthood, as recommended by international guidelines. The rationale is simple: because levels are genetically determined and relatively stable over time, a single test can provide lifelong risk information. Previously, testing was reserved for high-risk cases such as early cardiovascular events, familial hypercholesterolemia, or strong family histories of heart disease. The new approach reflects a shift toward earlier and broader risk detection.
Ana Moyá, an expert in lipid disorders within Spain’s primary care medical society Semergen, emphasises that Lp(a) is particularly relevant in patients already at risk. When combined with other risk factors, elevated Lp(a) can significantly increase overall cardiovascular danger. She notes that it is considered more atherogenic than LDL cholesterol and can lead to reclassification of a patient’s risk category, prompting more intensive treatment strategies.
However, Moyá also highlights a biological complexity that complicates interpretation. While Lp(a) is largely stable throughout life, it can show small variations of between 5% and 10%, and in women may fluctuate more significantly during hormonal transitions such as puberty, pregnancy, and menopause, where increases of up to 22% have been observed. These nuances further complicate how the test should be integrated into routine practice.
Beyond scientific debate, a major barrier remains practical implementation. Many hospitals lack the technical capacity to routinely perform the test, and many primary care physicians report uncertainty about how to interpret or act upon results. Moyá acknowledges that this knowledge gap is widespread, even among experienced clinicians. Escribano similarly notes that keeping up with evolving recommendations is challenging for general practitioners, despite the fact that guidance on Lp(a) testing has existed in Europe for years.
This disconnect between guidelines and practice has led to a growing phenomenon: patients ordering the test privately, discovering elevated results, and returning to their doctors with a simple but difficult question—what now? In many cases, clinicians must explain that while the risk is real, direct treatment options remain limited, shifting the focus instead to broader cardiovascular prevention.
Looking ahead, specialists are cautiously optimistic. Several experimental therapies are currently in development, with early clinical trials showing potential reductions in Lp(a) levels of up to 80–90%. If approved by regulators, these treatments could fundamentally change how the marker is managed in clinical practice, possibly by 2027 or later. Until then, however, the gap between diagnosis and treatment remains.
Existing drugs such as PCSK9 inhibitors, used primarily for familial hypercholesterolemia and high-risk cardiovascular patients, can reduce Lp(a) modestly—by around 20% to 25%—but are not specifically indicated for it. As a result, their impact remains secondary rather than definitive.
The central debate, therefore, is not whether Lp(a) can currently be treated, but whether it should be measured widely despite limited therapeutic options. Increasingly, the medical consensus leans toward yes. Knowing the risk, even without a direct remedy, is seen as valuable for shaping prevention strategies and improving long-term outcomes.
In the end, the story of Lp(a) reflects a broader tension in modern medicine: between advanced risk detection and limited intervention tools, between global scientific consensus and uneven local implementation. As this report from El País, referenced by Finanacil Times, makes clear, the question is no longer whether Lp(a) matters—but whether health systems are ready to act on what they already know.
